Copyright
©The Author(s) 2023.
World J Hepatol. Jun 27, 2023; 15(6): 775-785
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.775
Published online Jun 27, 2023. doi: 10.4254/wjh.v15.i6.775
Ref. | Tumor | No. | Correlations | Prognosis |
Kairaluoma et al[75] | HCC | 47-R; 212-NR | Not observed; Not observed | OS: TB negative vs TB positive; DSS: TB negative vs TB positive |
Wei et al[76] | HCC | 423 | Tumor subtypes, EMT related marker expression, FOXP3, PD-L1 and CD68 expressions; Frequent mast cell infiltration, p53 mutation (IS-TB type I); CTNNB1 mutation (IS-TB type IV) | DFS: Type II vs Type I + Type IV; Type III vs Type I + Type IV; OS: Type II vs Type I + Type IV; Type III vs Type I + Type IV |
Okubo et al[77] | CCC | 299 | Dif G1/G2vs Dif G3 | OS: TB negative vs TB positive |
Ogino et al[78] | EHCC-PH; EHCC-DC | 195; 115 | Grade, T, LI, VI, PN, LNM, RSM; Grade, Higher T, LI, VI, PN, LNM | OS: TB low vs TB ıntermediate vs TB high; OS: TB low vs TB high |
Tanaka et al[80] | ICC | 107 | Stage, Hilar invasion, Grade, VI, LNM, SM | RFS: TB negative vs TB positive; OS: TB negative vs TB positive |
Type 1 | 49 | NP | RFS: Not prognostic; OS: Not prognostic | |
Type 2 | 58 | NP | RFS: Not prognostic; OS: TB negative vs TB positive | |
EHCC-PH | 54 | LI | RFS TB negative vs TB positive; OS TB negative vs TB positive | |
EHCC-DC | 40 | VI | RFS: Not prognostic; OS: Not prognostic | |
Ito et al[81] | EHCC-PH | 78 | Grade, T, LNM, M | |
36 NT | Combined HA/PV Resection, Grade, T, LNM, M | DSS: TB low vs TB high; RFS: TB low vs TB high | ||
42 WT | Not observed | DSS: TB low vs TB high; RFS: Not prognostic | ||
Agostini-Vulaj et al[83] | EHCC; ICC | 58; 54 | Gender, Location, Grade, LNI, PNI, RSM; Gender, Location, Grade, LNI, PNI | DSS: TB ıntermediate vs TB high; RFS: TB ıntermediate vs TB high |
Budau et al[84] | ICC | 89 | NP | OS: TB Low vs TB Intermediate vs TB High; RFS TB Low vs TB Intermediate vs TB High ITTB, PTTB, TB |
Kosaka et al[85] | ICC | 235 | Size, Tumor type, Grade, VI, MBI, LNM | DSS: TB Low/Intermediate vs TB High; RFS: TB Low/Intermediate vs TB High |
Nakayama et al[82] | EHCC-DC | 65 | T, LNM, LI, VI, ZEB-1 expression, stage | OS: TB Low vs TB High |
Ref. | Tumor | Tumor budding criteria |
Kairaluoma et al[75] | HCC | Evaluation was performed according to median values; Negative: No buds were found; Positive: At least one bud was present |
Wei et al[76] | HCC | Association between TB and clinicopathological parameters; Grade 1 (0-4), Grade 2 (5-9), Grade 3 (≥ 10); For survival analysis; Low grade (0-9), High grade (≥ 10) |
Okubo et al[77] | CCC | Negative: < 5 budding focus; Positive: ≥ 5 budding focus |
Ogino et al[78] | EHCC-PH, EHCC-DC | Cut-off values of TB obtained by recursive partioning technique; For EHCC-PH; Low grade (0-4), Intermediate grade (5-11), High grade (≥ 12); For EHCC-DC; Low grade (0-4), High grade (≥ 5) |
Tanaka et al[80] | ICC, EHCC-PH, EHCC-DC | Low grade (0-4), Intermediate grade (5-9), High grade (≥10) |
Ito et al[81] | EHCC-PH | Low TB: < 5 budding focus; High TB: ≥ 5 budding focus |
Agostini-Vulaj et al[83] | ICC, EHCC | Grade 1 (0-4), Grade 2 (5-9), Grade 3 (≥ 10) |
Budau et al[84] | ICC | Grade 1 (0-4), Grade 2 (5-9), Grade 3 (≥ 10) |
Kosaka et al[85] | ICC | Low grade (0-4), Intermediate grade (5-9), High grade (≥ 10) |
Nakayama et al[82] | EHCC-DC | Low TB (0-4), High [TB Grade 2 (5-9) and 3 (≥ 10)] |
- Citation: Unal B, Celik MY, Gedik EO, Bassorgun CI, Elpek GO. Tumor budding as a potential prognostic marker in determining the behavior of primary liver cancers. World J Hepatol 2023; 15(6): 775-785
- URL: https://www.wjgnet.com/1948-5182/full/v15/i6/775.htm
- DOI: https://dx.doi.org/10.4254/wjh.v15.i6.775